Dapagliflozin is a selective inhibitor of SGLT2 with EC50 of 1.1 nM which is used to treat type 2 diabetes mellitus.

Canagliflozin is a novel C-glucoside with thiophene ring.

Empagliflozin is a selective inhibitor of SGLT-2 with IC50 of 3.1 nM.

Ipragliflozin is a selective inhibitor of SGLT2 with IC50 of 14 nM for hSGLT2.

Tofogliflozin is a potent and highly specific sodium/glucose cotransporter 2(SGLT2) inhibitor with Ki values of 2.9, 14.9, and 6.4 nM for human, rat, and mouse SGLT2.

LX4211 is an inhibitor of SGLT2 and SGLT1 with antidiabetic activity.